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Abstract 
In previous studies, the β -blocker carvedilol inhibited EGF-induced epidermal cell 
transformation and chemical carcinogen-induced mouse skin hyperplasia. As exposure to 
ultraviolet (UV) radiation leads to skin cancer, the present study examined whether 
carvedilol can prevent UV-induced carcinogenesis. Carvedilol absorbs UV like a 
sunscreen; thus, to separate pharmacological from sunscreen effects, 4-hydroxycarbazole 
(4-OHC), which absorbs UV to the same degree as carvedilol, served as control. JB6 P+ 
cells, an established epidermal model for studying tumor promotion, were used for 
evaluating the effect of carvedilol on UV-induced   neoplastic   transformation.   Both 
carvedilol   and 4-OHC (1 μmol/L) blocked transformation induced by chronic 
UV (15 mJ/cm2) exposure for 8 weeks. However, EGF-mediated transformation was 
inhibited by only carvedilol but not by 4-OHC. Carvedilol (1 and 5 μmol/L), but not 4-
OHC, attenuated UV-induced AP-1 and NF-kB luciferase reporter activity, suggesting a 
potential anti-inﬂammatory activity. In a single-dose UV (200 mJ/cm2)-induced  skin 
inﬂammation mouse  model, carveilol (10 μmol/L), applied topically after UV exposure, 
reduced skin hyperplasia and the levels of cyclobutane pyrimidine dimers, IL1b, IL6, and 
COX-2 in skin. In SKH-1 mice exposed to gradually increasing levels of UV (50–150 
mJ/cm2) three times a week for 25 weeks, topical administration of carvedilol (10 
μmol/L) after UV exposure increased tumor latency compared with control (week 18 vs. 
15), decreased incidence and multiplicity of squamous cell carcinomas, while 4-OHC had 
no effect. These data suggest that carvedilol has a novel chemopreventive activity and 
topical carvedilol following UV exposure may be repurposed for preventing skin 
inﬂammation and cancer.  
 
 
Introduction 
β-Adrenergic receptor (β-AR) antagonists, commonly called β-blockers, are usually used 
for cardiovascular disorders and  act via inhibiting catecholamines, i.e., epinephrine and 
norepinephrine, from triggering the body's "ﬁght or ﬂight" response to stress (1). Recent 
evidence suggests that catecholamines, by activating β-ARs, also play a role in 
carcinogenesis including skin carcinogenesis, possibly through inducing DNA damage 
(2), promoting transformation  (3,  4),  and  inhibiting  cutaneous  immunity (5). 
β-ARs are expressed in various cell types of human skin. Keratinocytes, the cells that 
make up the majority of the epidermis, express only the b2-AR while melanocytes 
express both β 1- and β 2-ARs (6, 7). Benign melanocytic nevi, atypical nevi, and 
malignant melanomas express β1- and β2-ARs, and expression of these receptors is 
greatest in malignant tumors (8). Ultraviolet (UV) irradiation can increase the secretion 
of epinephrine from keratinocytes while melanocytes synthesize norepinephrine but are 
unable to produce epinephrine (9). In melanocytes, the signaling through β-ARs promotes 
pigmentation in response to  epinephrine secreted from the neighboring keratinocytes (6). 
Thus, catecholamines and UV radiation may synergistically act on the skin 
microenvironment to promote carcinogenesis. Recent clinical and preclinical 
investigations have provided evidence that the use of β-blockers in combination with 
chemotherapy or radiotherapy reduced metastasis and prolonged the survival of patients 
with multiple cancers (10–19). For melanoma, epidemiological  studies  indicate  that  
long-term  use of β-blockers reduced progression and mortality (20, 21). However, the 
association between the use of β-blockers with cancer incidence is infrequently 
investigated, and their effects on cancer prevention remain controversial (22–24). Also, 
most of these studies focused on developed tumors, which are not the ideal model to 
evaluate the preventive effects of β-blockers. Interestingly, long-term use of the β -
blocker carvedilol is associated with reduced risk of many cancer types in a recent 
population-based cohort study (25), which is the largest retrospective cancer incidence  
study  focusing  on  a  single  β -blocker  involving  6,771 carvedilol users and the same 
number of non-user  controls. Carvedilol is a third-generation receptor subtype 
nonselectiveβ -blocker  with  antioxidant  and  anti-inﬂammatory  properties (26–28). 
Previous preclinical studies established carvedilol-mediated chemopreventive effects via 
inhibition of EGF-induced transformation of the non-tumorous mouse epidermal cell line 
JB6 Cl 41-5a (JB6 P+) and reduction of 7,12-dimethylbenz(a) anthracene (DMBA)-
induced epidermal hyperplasia in mice (29). Although the aforementioned studies are 
models of skin carcinogenesis, the effect of carvedilol should be examined in a more 
clinically relevant model—skin carcinogenesis induced by UV. Thus, in the present 
study, we tested the hypothesis that carvedilol prevents UV-induced skin cancer. 
  
Materials and Methods 
 
Compounds 
Carvedilol was purchased from Tocris Bioscience. 4-Hydroxycarbazole (4-OHC) and 
1,2-dimethoxybenzene was purchased from Sigma-Aldrich and epidermal growth factor 
(EGF) from Peprotech. Carvedilol and 4-OHC were reconstituted in dimethyl sulfoxide 
(DMSO) used in vitro or in acetone used in vivo, whereas EGF was prepared in PBS. All 
stocks are stored in -20°C and diluted right before each use. 
 
Cell culture 
JB6 Cl 41-5a (JB6 P+), purchased from ATCC in 2011, were cultured as described in the 
manufacturer's instruction with modification of using media containing 4% heat-
inactivated fetal bovine serum. HEK-293 cells were also obtained from ATCC in 2007 
and cultured in Dulbecco's MEM (Genesee Scientific) supplemented with 10% fetal 
bovine serum (Genesee Scientific) and 1% penicillin/streptomycin (Invitrogen). 
Authentication has not been done by the authors. The described experiments were 
conducted using cells of less than 10 passages after thawing. All cells from cell culture-
related experiments were incubated in a humidified atmosphere of 37°C and 5% 
CO2/95% air. 
 
 
 
 
UV–Vis spectral analysis 
Compounds were reconstituted in DMSO to a final concentration of 1 μmol/L (n ¼ 4) 
and subjected to complete UV–Vis spectral analysis using NanoDrop 2000c (Thermo 
Scientific). DMSO served as a blank with 750nmset to zero and subsequently used as a 
vehicle control. 
 
UV light source 
The UV lamps emitting UVB (280–320 nm; 54%of total energy), UVA(320–
400nm;37%of total energy),UVC(100–280nm; 2.0% of total energy) and Visible light 
(400–450 nm; 7.0% of total energy; catalog numbers #95-0042-08 and #95-0043-13; 
UVP; Supplementary Fig. S1) were used to irradiate in vitro and in vivo experiments. 
Stable power output (mW/cm2)was measured using a UVX radiometer (#97-0015-02, 
UVP) coupled with a sensor with a calibration point of 310 nm (UVX-31, #97-0016-04, 
UVP), and exposure time was calculated using the following formula: dose (mJ/cm2) = 
exposure time (s) x output intensity (mW/cm2). Quality control of the lamps and exposure 
time were calculated and monitored before each use of the lamps to account for changes 
in power output over time. 
 
Anchorage-independent growth assay of JB6 P+ cells promoted by EGF or UV 
EGF-mediated transformation of JB6 P+ cells was conducted in 96-well plates as 
previously described (29). Low-dose UV irradiation was used to transform the JB6 P+ 
cells following a modified method (30). In brief, radiant doses of 15 mJ/cm2 UV was 
applied 
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EGF-mediated transformation of JB6 P+ cells was conducted in 96-well plates as 
previously described (29). Low-dose UV irradiation was used to transform the JB6 P+ 
cells following a modified method (30). In brief, radiant doses of 15 mJ/cm2 UV was 
applied exposed to goat anti-rabbit IgG-HRP (Cell Signaling Technologies) diluted 
1:20,000 in 5% non-fat milk at room temperature for 60 minutes. Membranes were 
visualized with Super Signal West Pico Chemiluminescent Substrate (Thermo Fisher). 
 
Quantitative RT-PCR analysis 
Total RNA was isolated from whole skin tissue using TRIzol (Thermo Fisher) and 
RNeasy Mini kit (Qiagen). cDNA was obtained with the High Capacity cDNA Reverse 
Transcriptase Kit (Thermo Fisher). cDNA and PerfeCTa SYBR Green Supermix (Quanta 
Biosciences, Inc.) were combined with primers for mouse Il6, Il1b, and β -actin (The 
primer sequences are available upon request). Real-time PCR was performed on a CFX96 
Realtime thermal cycler detection system (Bio-Rad), and analyzed with the 2DDct with  
β -actin as the normalization control. 
 
UV-induced murine skin tumorigenesis 
A total of 42 six-week-old female SKH-1 mice (Charles River) were randomly 
divided into six groups. The groups were (i) n = 4 non-UV exposure vehicle treated, (ii) n 
¼ 4 non-UV exposure carvedilol treated, (iii) n = 4 non-UV exposure 4-OHC treated, 
(iv) n = 10 UV-exposed vehicle treated, (v) n ¼ 10 UV-exposed carvedilol treated, and 
(vi) n = 10 UV-exposed 4-OHC treated. Mice were topically treated with 200 mL acetone 
(vehicle), 10 μmol/L carvedilol or 4-OHC dissolved in 200 mL acetone three times per 
week for 2 weeks before UV exposure. The mice were irradiated with gradually 
increasing levels of UV 3 times a week for 25 weeks with an initial dose of 50 mJ/cm2 
that was increased each week by 25 mJ/cm2 to 150 mJ/cm2, which continued for the 
duration of the experiment. The treatment regimen was applied after UV irradiation and 
continued throughout the experiment. During the UV exposure mice roamed freely in 
acrylic cages on a rotating platform with rotational placement ensuring consistent and 
equal dorsal distribution of UV irradiation. Tumors of at least 1 mm in diameter were 
counted and measured weekly. At the end of the study, the mice were euthanized  
and tumorous and non-tumorous skin samples were excised and fixed in 10% formalin 
for pathological analysis. Hematoxylin and eosin (H&E)-stained sections of the tumors 
were examined by a board-certified pathologist. 
 
Statistical analysis 
Data are expressed as a mean + standard deviation unless stated otherwise. All 
plots were made using GraphPad Prism, and statistical analysis was conducted in 
GraphPad Prism and NCSS 2007. Specific statistical tests are detailed in the figure 
legends or text; for data dealing with tumor number, data are reported as median + 
median absolute deviation (MAD), and nonparametric analysis was used for statistical 
quantification. 
 
Results 
4-OHC as a sunscreen control for carvedilol 
The UV absorption spectrum of carvedilol and its non-β-ethanolamine R-groups 
4-OHC and 1,2-dimethoxybenzene was examined to identify a compound that may serve 
as a UV absorption control in the proceeding studies. As can been seen from Fig. 1A, the 
UV absorption profile of carvedilol is completely mimicked by equimolar concentrations 
of 4-OHC. Because 4-OHC lacks the required β -ethanolamine component of β -blockers, 
it can serve as a UV absorption (sunscreen) control. The absorption profile covers most 
of the emitted spectrum of the UV lamps used throughout this study (Supplementary Fig. 
S1). However, it is unclear whether interacting with β -AR is the mechanism for the 
chemopreventive properties of carvedilol. Therefore, the concentration-response effects 
of carvedilol and 4-OHC on EGF-mediated transformation of JB6 P+ cells were examined 
(Fig. 1B). As previously described, carvedilol inhibited EGF-induced JB6 P+ cell 
transformation in a dose-dependent manner (29), but 4-OHC had no effect. Thus, 4-OHC 
can serve as a sunscreen control in following experiments involving UV, allowing for 
separating the pharmacological and UV absorption properties of carvedilol. 
 
 
 
 
Figure 1. 
Establishing a sunscreen control for carvedilol. A, Structures of carvedilol and its 
potential UV absorption moieties are provided along with the key for the UV absorption 
spectrum shown near the structures. The thickness of the lines represents the mean + SD; 
n = 4. B, Effect of carvedilol and 4-OHC on EGF induced neoplastic transformation of 
JB6 P+ cells. Data are expressed as mean + SD; n = 8. Bars with different Greek letters 
are statistically different (P < 0.001) as per one-way ANOVA with Tukey–Kramer post 
hoc test. 
 
 
 
Effects of carvedilol or 4-OHC on UV-induced JB6 P+ cell transformation 
As 4-OHC absorbs UV irradiation, it is expected that 4-OHC will have some 
degree of UV protection, while carvedilol is hypothesized to provide greater preventive 
activity against UV induced effects due to its pharmacological activity. This hypothesis 
was first tested in the JB6 P+ cell transformation assay using UV as the tumor promoter 
because low and re-occurring dosages of UV irradiation can lead to malignant 
transformation of JB6 P+ cells (30). Treating JB6 P+ cells with 15 mJ/cm2 UV three times 
a week for 8 weeks then plating the cells in agar with growth media without any promoter 
or drugs resulted in more colonies than EGF as the promoter (48 + 4 vs. 35 + 4, P = 
0.002922, respectively; data expressed as median  median absolute deviation (MAD)). 
Incubation with 1 μmol/L carvedilol or 1 μmol/L4-OHC for the duration of experimental 
paradigm, except during UV exposure, statistically reduced chronic UV-induced colony 
formation by 64% and 59%, respectively (Fig. 2). Although carvedilol 
appears more effective than 4-OHC, it is not statistically different.  
 
 
Figure 2. 
Effect of carvedilol and 4-OHC on UV-induced JB6 P+ cell transformation. JB6 P+ cells 
were exposed to 15 mJ/cm2 UV 3 times per week for a total of 8 weeks in the presence or 
absence of test compounds then plated in the soft agar without any additional ligands; 
control cells were passaged along with the UV-treated cells. Data are expressed as mean 
+ SD; n = 6. Bars with different Greek letters are statistically different (P < 0.05 as well 
as P < 0.001) as per one-way ANOVA with Tukey–Kramer post hoc test. 
 
 
Effects of carvedilol or 4-OHC on UV-induced NF-kB and AP-1 activation 
The transcription factor activator protein-1 (AP-1) and NF-kB are principal 
mediators of skin carcinogenesis activated by UV irradiation (31, 32). To begin exploring 
the molecular mechanisms underlying the observed effects of carvedilol, UV-mediated 
activation of AP-1 and NF-kB were evaluated by dual luciferase assays in HEK-293 
cells. As shown in Fig. 3, a single low dose of UV (25 mJ/cm2) was sufficient to activate 
the transcription of NF-kB and AP-1. Carvedilol, but not 4-OHC, inhibited UV-mediated 
transcriptional activity of NF-kB and AP-1 when administered after UV exposure. To 
further confirm that carvedilol, but not 4-OHC, acts through a pharmacological 
mechanism, TNFa- and EGF-mediated NF-kB and AP-1 activation, respectively, were 
examined by dual luciferase assays in the absence and presence of carvedilol and 4-OHC. 
The results (data not shown) are similar to Fig. 3, where carvedilol, but not 4-OHC, 
inhibits NF-kB and AP-1 activation. These data further demonstrate that the observed 
UV-protective effects are pharmacological in nature and are not completely due to a 
sunscreen effect. 
 
Figure 3. 
Effect of carvedilol and 4-OHC on UV-induced NF-kB and AP-1 transcription factors. 
Effect of carvedilol on UV-induced NF-kB (A) and AP-1 (B) transactivation, as well as 
4-OHC on UV-induced NF-kB (C) and AP-1 (D) transactivation. HEK-293 cells 
expressing exogenously transfected AP-1 or NF-kB luciferase reporter and Renilla 
control reporter were treated with vehicle, 25 mJ/cm2 UV, carvedilol or 4-OHC following 
UV for 5 or 24 hours for NF-kB and AP-1 assays, respectively. Data are expressed as 
mean + SD; n ¼ 3. Bars with different Greek letters are statistically different (P < 0.05) 
as per one-way ANOVA with Tukey–Kramer post hoc test. 
Effects of topically applied carvedilol in a short-term UV mouse model 
The effects of carvedilol on UV-induced NF-kB activation supports its anti-
inflammatory activity. Although antioxidant and anti-inflammatory effect of carvedilol 
has been reported related to hypertension (28), its contribution to UV induced 
inflammation, a known factor leading to skin carcinogenesis (33, 34), is unclear. 
A short-term UV exposure model was chosen to address this question in vivo. A single 
dose of 200 mJ/cm2 UV was utilized to examine proximal effects of carvedilol treatment 
in SKH-1 mice after 6 and 24 hours. To investigate treatment protocols, the mice were 
treated with topical carvedilol (10 μmol/L) 2 hours before or immediately after UV 
irradiation. These two groups mirror a prophylactic treatment, such as the use of 
sunscreen, and treatment for a sunburn, respectively. Bifold thickness of dorsal 
epidermal skin was measured before and after UV treatment to examine the effect of 
carvedilol on UV-induced skin edema/hyperplasia. As expected, UV induced a rapid 
change in skin thickness (45% and 56% increase, 6 hours or 24 hours after irradiation, 
respectively; Supplementary Fig. S2), and the control groups not exposed to UV showed 
no change. Only carvedilol treatment immediately after UV exposure ("postCAR"), when 
examined after 24 hours, showed a statistical decrease in bifold skin thickness. 
UV exposure induces DNA damage in skin epidermis predominantly through the 
formation of CPD. The level of CPD was detected 6 hours after UV exposure and was 
visibly reduced after 24 hours (Fig. 4A). Treatment by carvedilol before or after UVB 
exposure resulted in 50.8% and 62.9% reduction in CPD, respectively, within 6 hours (P 
< 0.001 compared with control), but no statistical reduction by carvedilol was observed at 
24 hours (Fig. 4B). This result further indicates that carvedilol is not merely acting as a 
sunscreen as both the pre- and post-UVB exposure treatment blocked CPD formation, 
with the posttreatment displayingslightly less CPD. 
The short-term increase in dorsal skin bifold thickness is likely due to an 
inflammatory reaction to UV. Therefore, the effect of carvedilol on UV-induced IL1b 
(gene symbol: Il1b, Fig. 4C) and IL6 (gene symbol: Il6, Fig. 4D) expression was 
examined via quantitative RT-PCR. UV markedly increased IL1b and IL6 levels. 
Only the postCAR group statistically decreased IL1b and IL6, while pretreatment with 
carvedilol tended to show lower levels of both IL1b and IL6. Similarly, Western blots for 
cyclooxygenase 2 (COX-2; Fig. 4E) demonstrate that UV greatly increases COX-2 
levels and similarly only postCAR group statistically decreased COX-2 levels (Fig. 4F). 
 
 
Figure 4. 
Effect of carvedilol on short-term high-intensity UV radiation. A, Representative slot blot 
for CPD. Each band represents DNA from one mouse from each treatment group. 
Genomic DNA was isolated from the dorsal skin of mice irradiated with 200 mJ/cm2 UV 
as well as 2 hour pre- or immediately post-treated with 10 μmol/L carvedilol. B, CPD 
data are expressed as mean + SD; n = 4. Bars with different Greek letters are statistically 
different (P < 0.05) as per two-way ANOVA with Tukey–Kramer post hoc test. qPCR 
results from skin samples of the 6-hour group for IL-1b (C) and IL-6 (D). β-Actin was 
used as a normalization control, and data are expressed as mean + SD; n = 4 to 8. Bars 
with different Greek letters are statistically different (P < 0.05) as per one-way ANOVA 
with Kruskal–Wallis multiple-comparison Z value post hoc test. E, Representative 
Western blot for COX-2 and β-actin from skin samples of the 6-hour group. F, 
Radiometric quantification of COX-2 levels in skin samples of the 6-hour group. Data are 
expressed as mean + SD; n = 2 (Con) and 4 for all others. Bars with different Greek 
letters are statistically different (P < 0.05) as per one-way ANOVA with Tukey–Kramer 
post hoc test. 
 
Effects of topically applied carvedilol or 4-OHC on chronic UV induced skin 
tumorigenesis in mice 
 The encouraging result in the short-term model motivated us to 
further investigate the chemopreventive activity of carvedilol in a murine skin 
carcinogenesis model. SKH-1 mice were topically treated for 2 weeks with 200 mL 
vehicle control (acetone), carvedilol (10 μmol/L in acetone), or 4-OHC (10 μmol/L in 
acetone). The mice were next irradiated by gradually increasing levels of UV radiation 
from 50 mJ/cm2 to 150 mJ/cm2 three times a week for 25 weeks to induce skin tumors as 
has been documented previously (31). The drug treatment was applied immediately after 
each UV exposure to minimize sunscreen effects. At week 15, tumors became visible on 
both acetone (vehicle control) and 4-OHC (sunscreen control) groups, whereas 
carvedilol-treated animals showed a 3-week delayed onset of tumor incidence. Following 
this delayed start of tumorigenesis, the median incident week, tumors per mouse, and 
tumor diameter were statistically lower in the carvedilol group compared with the vehicle 
control and sunscreen control groups (Table 1). Aside from number and size of tumors, 
the tumors were visibly worse in the vehicle and sunscreen control groups (Fig. 5A). 
Additionally, in the vehicle and 4-OHC groups, one animal per group carried severe 
tumors which required immediate attention by IACUC and was euthanized early due to 
rapid tumor progression. Because there was no difference between the two controls, 
pathological identification of tumor type was only conducted on the UV and UV + 
carvedilol treated groups. Given the marked reductions in tumor formation, it is not 
surprising that the grade of measurable lesion is more severe in UV-treated mice than 
those treated with carvedilol after UV exposure (Fig. 5B). At week 25, the acetone group 
comprised of mice with 6.25 % poorly differentiated squamous cell carcinoma (pSCC) 
and 50% well differentiated SCC (wSCC) of the total tumors, whereas in the carvedilol 
group, no pSCC but only 33% wSCC were observed. Lastly, Cox regression analysis 
indicates that carvedilol slows the appearance of tumors compared with control, P = 
0.0159; moreover, the rate of tumor appearance on the vehicle and the sunscreen control 
groups was similar with 4-OHC–treated mice being slightly worse, P = 0.1746 (Fig. 5C). 
 
Table 1. Effects of topical carvedilol or 4-OHC treatment on the emergence and 
progression of UV-induced skin tumors 
 aOne mouse developed an infection of the skin and was excluded from the analysis. 
bTumors counted as any mass having a diameter of at least 1 mm before sacrificing the 
mouse. 
cData expressed as median + MAD; values with different Greek letters are statistically 
different (P < 0.05) as per one-way ANOVA with Kruskal–Wallis Z post hoc test. 
dData expressed as mean + SD; values with different Greek letters are statistically 
different (P < 0.05) as per one-way ANOVA with Kruskal–Wallis Z post hoc test. 
 
 
 
 
Figure 5. 
Effect of carvedilol and 4-OHC on the development of skin tumors in mice. A, 
Representative appearance of mice in each UV-exposure group at week 26. B, Summary 
of the skin lesions in UV- and carvedilol-treated groups. Epidermal lesions were 
identified as epidermal dysplasia, papilloma, and squamous cell carcinoma (SCC) that 
was subdivided into three categories: poorly differentiated (pSCC), well differentiated 
(wSCC), and in situ (iSCC). C, Cox regression analysis of the percentage of mice not 
bearing tumors; P¼0.0159 for carvedilol versus control and P = 0.1746 for 4-OHC versus 
control. 
 
 
Discussion 
The present study is a follow-up investigation of our previous report of the cancer 
chemopreventive effects of carvedilol (29). The key finding is that carvedilol protects 
skin against harmful effects induced by UV which is a well-known cause for skin cancer. 
To the best of our knowledge, this is the first study to demonstrate that a β -blocker, 
commonly used for cardiovascular diseases, attenuated UV-induced skin tumor 
development and other molecular changes. 
A pitfall with experiments involving UV is that the potential UV absorption 
properties of test agents may result in a false positive testing result. Therefore, an 
important and novel method used in this study is the inclusion of a sunscreen control 
based on the UV absorption properties of the experimental agent (carvedilol). The 
rationale for the sunscreen control is that if a test agent absorbs UV, it will have a 
sunscreen effect because the mechanism of action for commercial sunscreens is to absorb 
UV prior to the tissue absorbing UV. UV absorption is not uncommon for compounds 
under investigation as skin chemopreventive agents (35). For example, caffeine and its 
analogues display both sunscreenand cancer-preventive effects on skin (36). According to 
thepresence of the methoxybenzene ring and carbazole moieties (Fig. 1A), carvedilol was 
predicted to absorb UV, and the UV spectrum analysis showed that the carbazole moiety 
appears to be responsible for most of carvedilol-mediated UV absorption because 4-OHC 
absorbs essentially the same UV spectrum ascarvedilol (Fig. 1A). 4-OHC lacks the 
required β -ethanolamine component of β-blockers, so it is not a β -blocker. However, it 
is unclear whether the chemopreventive properties of carvedilol are attributed to the β -
blocking property. To evaluate 4-OHC's chemopreventive activity, the concentration-
response effects of carvedilol and 4-OHC on EGF-mediated transformation of JB6 P+ 
cells were compared. Obviously, when using EGF as the tumor promoter, the cells are 
not exposed to UV irradiation; thus, UV absorption is not a factor in this experiment. 
Because 4-OHC does not inhibit EGF-mediated transformation of JB6 P+ cells (Fig. 1B), 
4-OHC was next compared with carvedilol on UV-induced cell transformation. In this 
experiment, carvedilol or 4-OHC was added to the culture media and incubated with cells 
during the experimental course of 8 weeks. The cells were washed once and incubated in 
PBS right before each UV exposure; after exposure the cells were reexposed to culture 
media containing drugs. Although carvedilol or 4-OHC was not present in PBS when the 
cells were irradiated, the observed protective effects of 4-OHC suggest that the 
compounds were retained on the cell surface during the washing and contributed to a 
sunscreen effect. These data demonstrate the need for a sunscreen control. Thus, for the 
duration of the studies involving UV, sunscreen effects were avoided by treating the cells 
or animals after UV exposure, and/or by including 4-OHC as control. In the luciferases 
assays, when carvedilol and 4-OHC were administered after UV exposure, we obtained 
the expected results that carvedilol, but not 4-OHC, prevented UV-induced 
transcriptional activity of NF-kB and AP-1 (Fig. 3). Therefore, treatment after UV is an 
optimal approach to evaluate carvedilol's chemopreventive effects. Similar approaches 
can be used for other compounds, as an appropriate sunscreen control may not be easily 
found for all test agents. Both AP-1 and NF-kB play a causal role in tumor promotion and 
UV-induced inflammation (37) and are major mediators for development of human skin 
cancer (38, 39). Therefore, the anticancer mechanism of carvedilol may involve 
inhibition of AP-1 and NF-kB pathways, although the signaling cascade requires further 
investigation. Cellular assays offer simple modes for screening compounds, but do not 
recapitulate carcinogenesis within a heterogeneous tissue like the skin. Thus, to examine 
carvedilol's effects on UV-induced DNA damage and skin inflammation, a short protocol 
similar to what is used in cell culture was applied to SKH-1 mice (Fig. 4). Because the 
luciferase assay showed that 4-OHC lacked any effect, 4-OHC was not used in the short-
term studies. However, two treatment modalities were used: pre- and postexposure 
treatments. These two groups mirror a prophylactic treatment, such as the use of 
sunscreen, and a treatment for a sunburn, respectively. Skin bifold measurements 
demonstrate that there are rapid changes in skin thickness due to UV exposure 
in all groups. Carvedilol only statistically reduced skin thickness when treated after UV 
exposure, and this was detected only after 24 hours. Contrarily, DNA damage, as 
measured by CPD formation, was statistically reduced within 6 hours by both 
pre- and post-treatment with carvedilol. Rapid changes in skin thickness are most likely 
due to the skin hyperplasia and inflammation (40). Post-treatment with carvedilol 
inhibited UV-induced IL1b and IL6 mRNA production and attenuated COX-2 
expression. In each case, pretreatment showed no statistical effect. The difference in pre- 
and posttreatment at the molecular level is mirrored in the skin thickness assay, 
suggesting the changes seen at 6 hours contribute to the reduced skin thickness observed 
at 24 hours. The lack of an effect of pretreatment is not completely understood, but two 
possibilities underlie the lack of effect at the molecular level. First, the time difference 
from carvedilol administration to tissue collection between the two modalities is two 
hours, which is a long time when considering most signaling cascades are measured in 
minutes. Following UV exposure, the pharmacological actions of carvedilol, such as free 
radical scavenging, may take place in minutes. Second, UV may enhance the degradation 
of carvedilol, thus reducing its efficacy. The cellular assays and CPD assay suggest that it 
can work as a sunscreen, but that may preclude pharmacological actions as the compound 
could be altered by the UV radiation. Although more studies are necessary to decipher 
the mechanism of carvedilol in CPD formation, the data clearly indicate that carvedilol is 
either preventing DNA damage or enhancing repair in vivo. CPD assays were attempted 
in JB6 P+ cells, but carvedilol failed to prevent CPD formation (data not shown). This 
suggests that the effect of carvedilol on CPD formation is not a direct effect on the cells, 
but due to altering the system or microenvironment that indirectly reduces DNA damage 
or enhances repair. Regardless of the mechanism(s), the short-term experiments indicate 
that carvedilol would be best used after exposure to UV irradiation—a sunburn treatment. 
The short-term UV experiment utilizing 200 mJ/cm2 UV irradiation is a high dose 
and does not represent progression of skin cancer that, in humans, can occur after decades 
of sub-erythema exposure to UV irradiation. Fortunately, mice can model this 
progression in months, not decades, with repeated low, suberythema, doses of UV 
irradiation. As predicted by the short-term studies, post-exposure treatment with 
carvedilol protected against UV induced skin carcinogenesis, and 4-OHC, the sunscreen 
control, had no effect (Table 1 and Fig. 5). The 25-week exposure precludes investigating 
molecular mechanisms but provides a clinically relevant model to determine if carvedilol 
is truly a chemopreventive agent. These data confirm that carvedilol is protective when 
applied after UV exposure. However, further studies are required to find the optimal dose 
and identify the window after UV exposure that carvedilol remains an effective 
chemopreventive agent. 
β-Blockers, i.e., β -adrenergic receptor antagonists, are usually prescribed for 
cardiovascular disorders. Recently the role of β-blockers has been reported in preclinical 
and clinical oncology studies (for reviews, see refs. 1 and 41). However, few studies 
examined the role of β-blockers in cancer prevention, and fewer examined skin cancer. 
Foreshadowing the results presented herein are studies demonstarting that chronic stress 
increased susceptibility to UV-induced SCC in SKH-1 mice through the modulation of 
immune system and DNA repair (42, 43). Chronic stress leads to activation of the β-ARs 
(43); thus, β-blockers should help reduce stress-associated SCC. Therefore, carvedilol 
may help reduce SCC in vivo by multiple mechanisms, not only through 
antitransformation of the epidermis but also by blocking stress-related activation of β -
ARs and immunosuppression. 
The effects of carvedilol in some of the experiments on cell culture and in mice 
were not drastic, although many of these changes are statistically significant. Future 
studies are necessary to explore possibilities to enhance carvedilol's chemopreventive 
effects. One example includes testing more doses (in this study we mainly examined 1, 5, 
and 10 μmol/L) and it is feasible to increase the doses for topical treatment. Alternative 
approach is to use carvedilol analogues to determine if a compound can be identified with 
greater chemopreventive activity. The third method is to use skin targeting drug delivery 
system that concentrates carvedilol in the skin layers. 
Taken together, although carvedilol acts as a sunscreen, the collective data 
demonstrate that carvedilol's chemopreventive activity is pharmacological and not merely 
a sunscreen effect. These results are supported by a large population-based cohort study 
where long-term carvedilol use showed benefits relating to significant reduction of cancer 
risk across all cancer types (25). Based on our data and published evidence about the role 
of β -AR signaling in cancer, carvedilol may be a novel cancer-preventive agent targeting 
all the three stages of skin carcinogenesis. Topical carvedilol application should be 
considered as a novel treatment for skin cancer prevention. Also, because carvedilol is an 
FDA approved drug for treating chronic cardiovascular diseases with evidence of safety 
in long-term use, these results may be readily translated into clinical trials as a new 
approach for skin cancer chemoprevention. One obstacle for the use of carvedilol for 
preventive purpose is its potential cardiovasuclar effects. Further studies should 
determine whether the β -blocking moiety of carvedilol is responsible for the 
chemopreventive effects and whether β-ARs are the target for such effects. Additionally, 
delivery systems can be developed to trap carvedilol in the skin localizing the 
pharmacological action and preventing cardiovascular effects. 
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